Addex Therapeutics Balance Sheet

Financials in millions CHF. Fiscal year is January - December.

Millions CHF. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	1.64	3.34	3.87	6.96	20.48
Short-Term Investments	0.01	0.01	0	0	0.02
Cash & Short-Term Investments	1.64	3.35	3.87	6.96	20.5
Cash Growth	-50.91%	-13.40%	-44.45%	-66.05%	9.29%
Accounts Receivable	0.02	0.02	0.11	0.42	0.16
Other Receivables	-	-	0.04	0.18	0.16
Total Trade Receivables	0.02	0.02	0.15	0.6	0.32
Other Current Assets	0.02	0.18	0.22	0.27	1.12
Total Current Assets	1.68	3.54	4.23	7.83	21.94
Net Property, Plant & Equipment	0.03	0.04	0.35	0.4	0.54
Long-Term Investments	4.14	7.09	0.05	0.05	0.06
Other Long-Term Assets	0.51	-	-	-	-
Total Assets	6.36	10.68	4.64	8.28	22.54
Accounts Payable	1.19	0.79	2.38	3	3.85
Current Portion of Leases	0.01	0.01	0.27	0.29	0.29
Unearned Revenue	-	-	0.23	-	-
Total Current Liabilities	1.2	0.8	2.89	3.28	4.13
Long-Term Leases	0.03	0.03	0.07	0.09	0.19
Other Long-Term Liabilities	0.37	0.16	0.53	-	1.28
Total Long-Term Liabilities	0.4	0.2	0.6	0.09	1.48
Total Liabilities	1.6	1	3.5	3.37	5.61
Common Stock	2.19	1.84	1.84	1.15	49.27
Treasury Stock	-1.01	-0.87	-0.91	-6.28	-11.7
Additional Paid-in Capital	331.93	331	330.82	334.13	283.98
Accumulated Other Comprehensive Income	31.76	31.06	29.81	25.77	24.44
Retained Earnings	-360.09	-353.36	-360.42	-349.86	-329.06
Shareholders' Equity	4.77	9.68	1.15	4.91	16.93
Total Liabilities & Equity	6.36	10.68	4.64	8.28	22.54
Total Debt	0.03	0.04	0.34	0.37	0.48
Net Cash (Debt)	1.61	3.31	3.52	6.59	20.02
Net Cash Growth	-51.33%	-6.13%	-46.53%	-67.10%	10.04%
Net Cash Per Share	1.80	4.04	5.69	9.61	70.41
Book Value	4.77	9.68	1.15	4.91	16.93
Book Value Per Share	5.33	11.84	1.85	7.17	59.55
Tangible Book Value	4.77	9.68	1.15	4.91	16.93
Tangible Book Value Per Share	5.33	11.84	1.85	7.17	59.55

Updated May 1, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q